No Jitter is part of the Informa Tech Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Perhaps the most meaningful measure of a technology’s success lies in the universality of its acceptance. The completion of the Human Genome Project spawned the various ‘omics sciences nearly two decades ago. Since then, they have risen to prominence worldwide as a means for studying how genes, RNA, and proteins affect health and disease, and how they can be modified by drug treatments. ‘Omics assays are now a mainstay of drug discovery and development.
While the efficacy of genomics, transcriptomics, and proteomics for providing valuable information is irrefutable, they can be limited in their scope and utility. Download this article to discover how adding metabolomics to these other technologies can help paint a clearer picture of the phenotype.
Offered Free by: Metabolon
See All Resources from: Metabolon
